Cannabinoid Standards

Cannabinoids are a class of psychoactive substances that are among the most widely abused and readily available drugs in the world.1,2 These drugs can produce intense psychological and physiological effects including auditory and visual hallucinations, anxiety, and euphoria. Besides persistent illicit use, a growing body of research suggests that cannabinoids may offer therapeutic efficacy in the treatment of many ailments from arthritis and chronic pain to glaucoma, epilepsy, and cancer.3

Concomitant with the rising popularity and cultural acceptance of cannabinoid use has been the emergence of synthetic cannabinoids. These compounds mimic the natural cannabinoids found in Cannabis plants, such as Δ9-tetrahydrocannabinol (THC). According to the United Nations Office on Drugs and Crime (UNODC), synthetic cannabinoids constitute the fastest growing group of novel psychoactive substances (NPS) in illicit drug markets.4 As of March, 2015, over 30 countries in the world have adopted regulatory responses to control emerging synthetic cannabinoids such as UR-144, XLR11, AKB48, PB-22, 5F-PB-22, AB FUBINACA, and ADB-PINACA.5

The market for recreational and medical Cannabis in the US, facilitated by changes in state laws towards legalization and decriminalization of Cannabis, is rapidly growing with sales expected to eclipse $10 billion by 2018.6 Because of their prevalence in drugged driving and medicolegal investigations, cannabinoids are routinely analyzed using GC/MS and LC/MS methods in forensic and clinical toxicology applications including postmortem, urine, and confirmatory drug testing. In North America and Europe, medical Cannabis testing laboratories have introduced chromatographic MS-based methods to quantify cannabinoids in medical and recreational Cannabis for assessing potency, cannabinoid profile, and specific therapeutic benefit.8

Cerilliant’s Certified Spiking Solutions® for THC and synthetic cannabinoids, including metabolites and stable-labeled internal standards, are each supplied in a convenient, quantitative, DEA-exempt solution. Cerilliant reference standards are manufactured and certified to the highest industry standards including ISO Guide 34 and ISO/IEC 17025. Each Certified Spiking Solution® is supported by a comprehensive Certificate of Analysis (COA) which provides all analytical data and uncertainty and traceability information to support regulatory requirements.

Materials

     

References

  1. http://www.unodc.org/documents/data-and analysis/WDR2012/WDR_2012_web_small.pdf
  2. Xu QA and Madden TL. LC-MS in Drug Bioanalysis. New York, Springer, 2012
  3. Armentano, P.; Carter, G.; Sulak, D.; Goldstein,E. T.: Emerging Clinical Applications For Cannabis and Cannabinoids: A Review of theRecent Scientific Literature. Sixth Edition. 2014.4. http://www.vice.com/read/floridians-are-losing-their-minds-on-synthetic-cannabis
  4. http://www.emcdda.europa.eu/publications/edr/trends-developments/2014
  5. http://www.descentralizadrogas.gov.co/wp-content/uploads/2015/03/
    Global_SMART_Update_13_web.pdf

  6. http://www.arcviewmarketresearch.com/download-the-executive-summary
  7. http://www.emcdda.europa.eu/attachements.cfm/att_53383_EN_emcdda-cannabis-mon-vol1-ch14-web.pdf
  8. http://liq.wa.gov/publications/Marijuana/BOTEC%20reports/1c-Testing-for-Psychoactive-Agents-Final.pdf

 

Related Links